Stay updated on Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Sign up to get notified when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.

Latest updates to the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3, reflecting a change to the site’s revision label without altering the underlying study record content.SummaryDifference0.1%

- Check24 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check53 days agoChange Detected- Revision history updated: v3.5.0 added; v3.4.3 removed.SummaryDifference0.1%

- Check60 days agoChange DetectedA new revision entry v3.4.3 was added to the history and the previous revision v3.4.2 was removed.SummaryDifference0.1%

- Check89 days agoChange DetectedAdded Revision: v3.4.2 to the history and removed the older funding-lapse notice and Revision: v3.4.1; this is an administrative update with no effect on the study data.SummaryDifference0.5%

- Check96 days agoChange DetectedNotice about lapse in government funding added; page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

Stay in the know with updates to Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.